Stockreport

A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF Trevi Therapeutics (TRVI) recently completed its end of phase 2 meeting with the FDA for its idiopathic pulmonary fibrosis related chronic cough program. This gives inv [Read more]